Pfizer Pushes Back, Metsera Holds Its Ground
Metsera disclosed a growing tension between the two sides, stating that Pfizer disputes the company’s right to even deliver the notice acknowledging Novo Nordisk’s proposal.
“Pfizer has informed Metsera that it does not believe Metsera has the right to deliver the notice,” the biotech said, adding, “Metsera disagrees with Pfizer’s view.”
Despite the turbulence, Metsera confirmed that its existing merger agreement with Pfizer remains in full effect and that its board continues to recommend the deal — at least for now.
Novo Nordisk Aims to Strengthen Its Grip on Obesity Drug Market
Novo Nordisk confirmed the offer in a separate statement, emphasizing that the acquisition would align perfectly with its mission to expand access to innovative incretin and nonincretin therapies targeting obesity and diabetes.
“An acquisition would provide Novo Nordisk the opportunity to maximize Metsera’s complementary portfolio and capabilities,” the company stated.
Metsera’s cutting-edge research into oral and injectable incretin-based treatments—potentially offering next-generation weight management and metabolic solutions—has made it a coveted target in the industry’s escalating race to address global obesity.
